CD274 and neoplasm: Despite some limitations, the assessment of PD-L1 levels via immunohistochemistry (IHC) staining in formalin-fixed paraffin-embedded tumor tissue samples is currently the only biomarker approved for clinical use, and is fully integrated into routine clinical practice20,21.